Fresenius Kabi releases PEMEtrexed for Injection, USP, a generic equivalent to Alimta. Produced in the United States, PEMEtrexed for Injection, USP is designed as an affordable treatment option for adult patients with non-squamous non-small cell lung cancer and malignant pleural mesothelioma. The product is available in four presentations: 100 mg per single dose vial, 500 mg per single dose vial, 750 mg per single dose vial, and 1 gram per single dose vial. This product is included in Fresenius Kabi’s KabiConnect program, part of the KabiCare patient support program offering copay assistance to eligible US patients.